Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
Launched by MCMASTER UNIVERSITY · Jul 31, 2023
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called intravesical mitomycin C (MMC) to see if it helps prevent the return of cancer in the bladder after doctors perform a procedure called ureteroscopy. This procedure is used to look at the upper urinary tract when there is a suspicion of a specific type of cancer called upper tract urothelial carcinoma (UTUC). The trial will involve 40 patients who will be randomly assigned to either receive MMC or no treatment at all. The goal is to find out if MMC can reduce the chances of cancer coming back in the bladder over two years.
To be eligible for this study, participants must have a suspected diagnosis of UTUC and need to have undergone a ureteroscopy where cancer was found. However, individuals with a history of bladder cancer, recent ureteroscopy, certain health conditions, or who are pregnant or breastfeeding will not be able to participate. If someone joins the study, they can expect to be monitored for any side effects and how well the treatment works over the next couple of years. This trial is currently not recruiting participants yet, but it aims to gather important information that could lead to larger studies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suspected upper tract urothelial carcinoma (UTUC)
- • Diagnostic ureteroscopy required
- • Tumor suggestive of upper tract urothelial carcinoma (UTUC) found on ureteroscopy
- Exclusion Criteria:
- • Prior or concomitant urothelial carcinoma of the bladder
- • History of UTUC
- • Ureteroscopy within the preceding six months
- • Untreated urinary tract infection
- • Suspected or confirmed perforation of the upper or lower urinary tract
- • Lower urinary tract fistula
- • Leukopenia or thrombocytopenia
- • ECOG performance status 2 or greater
- • Known hypersensitivity to mitomycin C
- • Pregnancy or breastfeeding
- • Lack of capacity to consent
About Mcmaster University
McMaster University, a leading research institution located in Hamilton, Ontario, Canada, is renowned for its innovative approach to education and its commitment to advancing healthcare through rigorous clinical research. The university's diverse research programs are supported by a multidisciplinary team of experts dedicated to improving patient outcomes and public health. With a strong emphasis on evidence-based medicine, McMaster University actively engages in clinical trials that explore new therapies, interventions, and health technologies, fostering collaboration among researchers, healthcare professionals, and industry partners to translate findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported